NCT05150236进行中（未招募）2 期
Phase II Study of Radionuclide 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With MetastaticCastration Resistant Prostate Cancer (mCRPC)
Australian and New Zealand Urogenital and Prostate Cancer Trials Group8 个研究点 分布在 1 个国家目标入组 93 人开始时间: 2022年4月29日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 93
- 试验地点
- 8
- 主要终点
- PSA progression free survival (PSA-PFS) at 1 year (PCWG3)
研究概览
简要总结
This phase II study will investigate the activity and safety of radionuclide 177Lu-PSMA therapy versus 177Lu-PSMA in combination with Ipilimumab and Nivolumab in patients with metastatic castrate resistant prostate cancer (mCRPC).
详细描述
This is an open label, randomised, stratified, multicentre phase 2 clinical trial recruiting 110 participants over 18 months and followed for 12 months. Participants will be randomised to 177Lu-PSMA in combination with Ipilimumab and Nivolumab and 177Lu-PSMA alone in a 2:1 ratio (using minimisation with a random component) stratified by prior exposure to docetaxel.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Aged 18 years or older, with histologically confirmed adenocarcinoma of the prostate.
- •Castration-resistant metastatic prostate cancer (defined as disease progressing despite castration by orchidectomy or ongoing luteinising hormone-releasing hormone agonist or antagonist).
- •Patients must have progressed on prior novel AR targeted agents for treatment of prostate cancer. Progressive disease defined by at least one of the following:
- •PSA progression, minimum of two rising PSA values from a baseline measurement with an interval of ≥ 1 week between each measurement. The PSA value at screening should be ≥ 5ng/ml
- •Soft tissue or visceral disease progression as per RECIST 1.1
- •Bone progression: ≥ 2 new lesions on bone scan as per PCWG3
- •Target or non-target lesions according to RECIST 1.1 and PCWG3
- •Significant PSMA avidity on PET/CT using 68GaPSMA, defined as SUVmax ≥15 at a site of disease, and SUVmax ≥ 10 at other sites of disease ≥10mm (where there is no impact from partial voluming.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-
- •Adequate bone marrow, hepatic and renal function documented within 28 days of registration, defined as:
- •Haemoglobin ≥90 g/L independent of transfusions (no red blood cell transfusion in last 4 weeks)
- •Absolute neutrophil count ≥1.5x109/L
- •Platelets ≥100 x109/L
- •Total bilirubin ≤1.5 x upper limit of normal (ULN) except for patients with known Gilbert's syndrome
- •Aspartate transaminase (AST/SGOT) and alanine transaminase (ALT/SGPT) ≤2.5 × ULN or ≤5 × ULN for participants with liver metastases
- •Serum creatinine ≤1.5 x ULN or a calculated creatinine clearance > 50mL/min (Cockcroft-Gault equation)
- •Patients must have a life expectancy ≥ 24 weeks.
- •Willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments
- •Signed, written informed consent.
排除标准
- •Prostate cancer with known significant sarcomatoid, spindle cell or neuroendocrine cell components, or metastasis of other cancers to the prostate.
- •18F-FDG-PET/CT SUVmax ≥10 at a site of measurable disease with no concurrent PSMA expression > 10mm
- •Prior treatment with anti-PD1, anti-PD-L1/L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways.
- •Patients must not have had more than one line of chemotherapy. If a patient has had docetaxel chemotherapy for hormone sensitive or castrate resistant setting, this will be considered one line.
- •Prior treatment with 177Lu-PSMA.
- •Patients with active, known, or suspected autoimmune disease. Sjogren's syndrome is considered an autoimmune disease. Exceptions: Patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to an autoimmune condition only requiring hormone replacement, or conditions not expected to recur in the absence of an external trigger, may be eligible.
- •Patients with a condition requiring systemic treatment with either corticosteroids (>10mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of registration. Inhaled or topical steroids, and adrenal replacement doses ≤ 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- •Participants must have recovered from all AE due to previous therapies to ≤Grade 1 or baseline. Participants with ≤ Grade 2 neuropathy may be eligible.
- •Active malignancies within the previous 2-years with >30% probability of recurrence within 1 year. Melanoma in situ, basal cell or squamous cell carcinomas of skin, are permitted.
- •Significant infection, including chronic active hepatitis B, hepatitis C, or HIV. Testing for these is not mandatory unless clinically indicated.
- •Radiation or surgery within 2 weeks of randomisation.
- •Previous history of interstitial lung disease or non-infectious pneumonitis.
- •Administration of a live vaccine within 30 days prior to the first dose of study drug.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Inadequate contraception. Men must have been surgically sterilised or use a (double if required) barrier method of contraception.
研究组 & 干预措施
Combination 177Lu-PSMA-617, Ipilimumab & Nivolumab
Experimental
177Lu-PSMA (7.5GBq) given every 6 weeks up to 6 cycles in combination with concurrent ipilimumab (3mg/kg Q6W x 4 doses) and nivolumab (1mg/kg Q3W x 8 doses) followed by nivolumab monotherapy (480mg Q4W up to 18 doses) or until disease progression or unacceptable toxicity.
干预措施: 177Lu-PSMA-617 (Drug)
Combination 177Lu-PSMA-617, Ipilimumab & Nivolumab
Experimental
177Lu-PSMA (7.5GBq) given every 6 weeks up to 6 cycles in combination with concurrent ipilimumab (3mg/kg Q6W x 4 doses) and nivolumab (1mg/kg Q3W x 8 doses) followed by nivolumab monotherapy (480mg Q4W up to 18 doses) or until disease progression or unacceptable toxicity.
干预措施: Ipilimumab (Drug)
Combination 177Lu-PSMA-617, Ipilimumab & Nivolumab
Experimental
177Lu-PSMA (7.5GBq) given every 6 weeks up to 6 cycles in combination with concurrent ipilimumab (3mg/kg Q6W x 4 doses) and nivolumab (1mg/kg Q3W x 8 doses) followed by nivolumab monotherapy (480mg Q4W up to 18 doses) or until disease progression or unacceptable toxicity.
干预措施: Nivolumab (Drug)
177Lu-PSMA-617
Experimental
177Lu-PSMA (7.5GBq) given every 6 weeks up to 6 cycles or until disease progression or unacceptable toxicity.
干预措施: 177Lu-PSMA-617 (Drug)
结局指标
主要结局
PSA progression free survival (PSA-PFS) at 1 year (PCWG3)
时间窗: Date of randomisation to the date of first evidence of PSA progression at 53 weeks post randomisation.
PSA progression is defined as a rise in PSA by ≥ 25% AND ≥ 2 ng/mL above the nadir (lowest PSA point). This needs to be confirmed by a repeat PSA performed at least 3 weeks later.
次要结局
- Time to treatment response(Date of randomisation through to study completion, approximately 3 years from start of recruitment.)
- Overall survival (OS)(Through to study completion, approximately 3 years from start of recruitment.)
- Frequency and severity of adverse events (CTCAE v5.0)(Date of first dose of study treatment until 100 days after cessation of study treatment.)
- PSA progression free survival (PCWG3)(Date of randomisation through to study completion, approximately 3 years from start of recruitment.)
- Objective response rate (ORR)(Date of randomisation through to study completion, approximately 3 years from start of recruitment.)
- Duration of response(Date of randomisation through to first radiological progression or through to study completion, approximately 3 years from start of recruitment.)
- PSA response rate (PSA-RR)(Date of randomisation through to study completion, approximately 3 years from start of recruitment. Early rises in PSA prior to 12 weeks will be disregarded in determining PSA response.)
- Radiological progression free survival (PCWG3/RECIST1.1)(Date of randomisation to the date of first evidence of progression on imaging (PCWG3 criteria for bone lesions and RECIST 1.1 for soft tissue lesions) assessed every 12 weeks through to study completion, approximately 3 years from start of recruitment.)
- Aspects of Health Related Quality of Life (HRQoL) - 2(Within 7 days prior to randomisation, assessed every 12 weeks, through to study completion, approximately 3 years from start of recruitment.)
- Aspects of Health Related Quality of Life (HRQoL) - 1(Within 7 days prior to randomisation, assessed every 12 weeks, through to study completion, approximately 3 years from start of recruitment.)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
2 期
Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer PatientsSalivary Gland CancerSalivary Duct CarcinomaAdenoid Cystic CarcinomaNCT04291300Radboud University Medical Center12
已完成
1 期
PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)Metastatic Castration Resistant Prostate CancerNCT03658447Peter MacCallum Cancer Centre, Australia37
已完成
1 期
Radionuclide therapy using 177Lu-PSMA: a pilot study in men with castrate-resistant prostate cancer (LuPSMA trial)castrate-resistant prostate cancerACTRN12618001552279St Vincent's Hospital15
招募中
2 期
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA TrialCastration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8NCT06288113Jonsson Comprehensive Cancer Center40
已完成
1 期
An early phase clinical trial evaluating the effectiveness of treatment of 177Lu-PSMA with idronoxil in men with castrate-resistant prostate cancer (LuPin Trial)ACTRN12618001073291St Vincent's Hospital Sydney56